DOP2014000077A - Preparación de liberación sostenida que contiene pioglitazona o una sal de esta - Google Patents

Preparación de liberación sostenida que contiene pioglitazona o una sal de esta

Info

Publication number
DOP2014000077A
DOP2014000077A DO2014000077A DO2014000077A DOP2014000077A DO P2014000077 A DOP2014000077 A DO P2014000077A DO 2014000077 A DO2014000077 A DO 2014000077A DO 2014000077 A DO2014000077 A DO 2014000077A DO P2014000077 A DOP2014000077 A DO P2014000077A
Authority
DO
Dominican Republic
Prior art keywords
salt
sustained release
pioglitazone
preparation
containing pioglitazone
Prior art date
Application number
DO2014000077A
Other languages
English (en)
Spanish (es)
Inventor
Yutaka Tanoue
Yusuke Murakawa
Yumiko Ishii
Kaoru Takenaka
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47178262&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2014000077(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of DOP2014000077A publication Critical patent/DOP2014000077A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DO2014000077A 2011-10-21 2014-04-15 Preparación de liberación sostenida que contiene pioglitazona o una sal de esta DOP2014000077A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2011232302 2011-10-21

Publications (1)

Publication Number Publication Date
DOP2014000077A true DOP2014000077A (es) 2014-07-15

Family

ID=47178262

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2014000077A DOP2014000077A (es) 2011-10-21 2014-04-15 Preparación de liberación sostenida que contiene pioglitazona o una sal de esta

Country Status (30)

Country Link
US (1) US9907789B2 (enExample)
EP (1) EP2768487B1 (enExample)
JP (1) JP6093762B2 (enExample)
KR (1) KR20140081826A (enExample)
CN (1) CN104039313A (enExample)
AP (1) AP2014007645A0 (enExample)
AR (1) AR088398A1 (enExample)
AU (1) AU2012326976B2 (enExample)
BR (1) BR112014008744A2 (enExample)
CA (1) CA2852417A1 (enExample)
CL (1) CL2014000992A1 (enExample)
CO (1) CO6960544A2 (enExample)
CR (1) CR20140213A (enExample)
DO (1) DOP2014000077A (enExample)
EA (1) EA201490840A1 (enExample)
EC (1) ECSP14013328A (enExample)
IL (1) IL232114A0 (enExample)
IN (1) IN2014DN03169A (enExample)
MA (1) MA35717B1 (enExample)
MX (1) MX2014004679A (enExample)
NZ (1) NZ624275A (enExample)
PE (1) PE20141189A1 (enExample)
PH (1) PH12014500856A1 (enExample)
SG (2) SG2014012025A (enExample)
TN (1) TN2014000152A1 (enExample)
TW (1) TW201323018A (enExample)
UA (1) UA113858C2 (enExample)
UY (1) UY34403A (enExample)
WO (1) WO2013058409A1 (enExample)
ZA (1) ZA201403103B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012326976B2 (en) 2011-10-21 2017-08-17 Takeda Pharmaceutical Company Limited Sustained-release preparation
US9096586B2 (en) 2012-04-20 2015-08-04 Gilead Sciences, Inc. Therapeutic compounds
US20150141517A1 (en) * 2013-11-15 2015-05-21 Shin-Etsu Chemical Co., Ltd. Granulated composite, rapid release tablet and method for producing same
KR102485766B1 (ko) 2019-12-11 2023-01-09 한국유나이티드제약 주식회사 생체이용률이 향상된 피오글리타존 함유 약학조성물
UY39094A (es) * 2020-02-27 2021-07-30 Hk Inno N Corp Composición farmacéutica que comprende compuesto derivado de bencimidazol
JP2023066053A (ja) * 2021-10-28 2023-05-15 東和薬品株式会社 放出制御医薬組成物
WO2025064867A1 (en) * 2023-09-21 2025-03-27 Yuva Biosciences, Inc. Delivery system for mitochondrial health enhancers

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810502A (en) 1987-02-27 1989-03-07 Alza Corporation Pseudoephedrine brompheniramine therapy
US4820522A (en) 1987-07-27 1989-04-11 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
JPH0624991A (ja) 1991-06-20 1994-02-01 Tokyo Tanabe Co Ltd ウルソデスオキシコール酸持続性製剤
JPH0624959A (ja) 1991-10-04 1994-02-01 Bayer Yakuhin Kk 胃内浮遊型薬物徐放性固形製剤
DE69332081T2 (de) 1992-09-18 2003-02-06 Yamanouchi Pharmaceutical Co., Ltd. Hydrogelzubereitung mit verzögerter freisetzung
JPH06316517A (ja) 1993-02-22 1994-11-15 Grelan Pharmaceut Co Ltd 放出制御製剤
AU8532798A (en) 1997-06-13 1998-12-30 Roland Bodmeier Compounds which delay the release of active substances
US6191154B1 (en) 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
US20040219208A1 (en) 2001-08-03 2004-11-04 Ryu Kawamura Sustained-release medicines
US9060941B2 (en) 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
KR20120034211A (ko) 2002-09-20 2012-04-10 안드렉스 랩스 엘엘씨 약제학적 정제
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
JP4493970B2 (ja) 2002-10-16 2010-06-30 武田薬品工業株式会社 持続性製剤
IN192749B (enExample) 2002-11-15 2004-05-15 Ranbaxy Lab Ltd
US7442387B2 (en) 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
CA2519208A1 (en) 2003-03-17 2004-09-30 Takeda Pharmaceutical Company Limited Controlled release composition
JP4933033B2 (ja) 2003-03-17 2012-05-16 武田薬品工業株式会社 放出制御組成物
CA2528164A1 (en) 2003-06-06 2004-12-16 Takeda Pharmaceutical Company Limited Solid preparation
JP2005015477A (ja) 2003-06-06 2005-01-20 Takeda Chem Ind Ltd 固形製剤
US20060003002A1 (en) 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
JP4739189B2 (ja) 2004-04-14 2011-08-03 武田薬品工業株式会社 固形製剤
BRPI0514416A (pt) 2004-08-31 2008-06-10 Pfizer Prod Inc formas de dosagem de liberação controlada combinando liberação imediata e liberação controlada de um fármaco de baixa solubilidade
EA200800880A1 (ru) 2005-09-22 2009-02-27 Смитклайн Бичам (Корк) Лимитед Комбинация росиглитазона и донепезила, предназначенная для улучшения когнитивной функции
WO2007054976A2 (en) 2005-11-08 2007-05-18 Panacea Biotec Ltd. Lipid based controlled release pharmaceutical composition
AU2006328328B2 (en) 2005-12-22 2012-08-30 Takeda Pharmaceutical Company Limited Solid preparation containing an insulin sensitizer
EP2002828B1 (en) 2006-03-30 2019-08-07 Nippon Zoki Pharmaceutical Co. Ltd. Solid pharmaceutical preparation
WO2007126135A1 (en) 2006-04-27 2007-11-08 Takeda Pharmaceutical Company Limited Pharmaceutical composition of angiotensin ii antagonists with pioglitazone hcl
JP5467870B2 (ja) 2007-02-09 2014-04-09 アルファファーム ピーティーワイ リミテッド 異なる物理的形態の２種以上の有効医薬成分を含有する投薬形態
TW200914006A (en) * 2007-07-12 2009-04-01 Takeda Pharmaceutical Coated preparation
CN101269040A (zh) 2008-05-16 2008-09-24 北京正大绿洲医药科技有限公司 盐酸吡格列酮缓释滴丸及其制备方法
TWI478712B (zh) * 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
US8445190B2 (en) 2008-09-30 2013-05-21 The Trustees Of The University Of Pennsylvania Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors
JP5827952B2 (ja) 2009-10-09 2015-12-02 ユンジン・ファーム・カンパニー・リミテッドＹｕｎｇｊｉｎ Ｐｈａｒｍ． Ｃｏ． Ｌｔｄ． 速効性と持続性を同時に有する薬剤学的組成物
JP2011232302A (ja) 2010-04-30 2011-11-17 Ricoh Elemex Corp 画像検査方法及び画像検査装置
CN101884627B (zh) 2010-07-07 2012-01-25 青岛黄海制药有限责任公司 盐酸吡格列酮胃内滞留缓释片及其制备方法
EA201391017A1 (ru) * 2011-01-10 2014-04-30 Зинфандел Фармасьютикалз, Инк. Способы и готовые лекарственные формы для лечения болезни альцгеймера
AU2012326976B2 (en) 2011-10-21 2017-08-17 Takeda Pharmaceutical Company Limited Sustained-release preparation
KR20160056691A (ko) 2014-11-12 2016-05-20 삼성에스디아이 주식회사 이차전지

Also Published As

Publication number Publication date
AU2012326976B2 (en) 2017-08-17
AU2012326976A1 (en) 2014-05-29
CN104039313A (zh) 2014-09-10
PH12014500856A1 (en) 2014-05-19
KR20140081826A (ko) 2014-07-01
US9907789B2 (en) 2018-03-06
TN2014000152A1 (en) 2015-09-30
EA201490840A1 (ru) 2014-08-29
AU2012326976A2 (en) 2014-06-12
SG10201700121YA (en) 2017-03-30
US20140248362A1 (en) 2014-09-04
TW201323018A (zh) 2013-06-16
BR112014008744A2 (pt) 2017-04-18
WO2013058409A1 (en) 2013-04-25
EP2768487B1 (en) 2020-06-03
CL2014000992A1 (es) 2014-09-05
UA113858C2 (uk) 2017-03-27
CR20140213A (es) 2014-06-18
IN2014DN03169A (enExample) 2015-05-22
UY34403A (es) 2013-05-31
EP2768487A1 (en) 2014-08-27
AP2014007645A0 (en) 2014-05-31
IL232114A0 (en) 2014-06-30
ECSP14013328A (es) 2014-05-31
AR088398A1 (es) 2014-05-28
SG2014012025A (en) 2014-06-27
PE20141189A1 (es) 2014-09-24
NZ624275A (en) 2016-09-30
CO6960544A2 (es) 2014-05-30
CA2852417A1 (en) 2013-04-25
JP6093762B2 (ja) 2017-03-08
ZA201403103B (en) 2015-08-26
MA35717B1 (fr) 2014-12-01
JP2014530802A (ja) 2014-11-20
MX2014004679A (es) 2014-08-01

Similar Documents

Publication Publication Date Title
ECSP14013328A (es) Preparacion de liberacion sostenida
GT201200322A (es) Derivados de carbamato de hexafluoroisoprofilo, su preparacion y su aplicacion en terapeutica
CL2015000574A1 (es) Formulaciones acuosas estables de adalimumab.
BR112014014558A8 (pt) composição farmacêutica, uso de um antagonista de crth2 e de um inibidor de bomba de prótons, e, kit para o tratamento de esofagite eosinofílica
CL2012002441A1 (es) Composicion natural que consiste en a) un sindetico hidrofilo, b) un sindetico hidrofobo que se selecciona de oxido de amina, c) un compuesto de biguanida o una sal de amonio cuaternario y opcionalmente otros ingredientes.
IN2014MN02213A (enExample)
EA201391212A1 (ru) Новые применения хлорида холина в агрохимических препаратах
MX378502B (es) Formulaciones de anticuerpos biespecificos anti-il-4/anti-il-13.
ECSP11011001A (es) Composición farmacéutica sólida
MY146947A (en) Antiparasitic agent for fish and method of controlling proliferation of fish parasites
JO3683B1 (ar) صياغة صلبة عبر الفم تحتوي على إرينوتيكان وطريقة لتحضيرها
BR112014002845A2 (pt) “composto, sal farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto”
CL2015001565A1 (es) Composición, en forma de suspensión acuosa, que comprende al menos un compuesto de triazina, un principio activo adicional y uno o más tensioactivos; kit que comprende la composición; método de preparación y uso de un tesioactivo.
TR201010683A1 (tr) Vildagliptin formülasyonları.
TR201009394A2 (tr) Geliştirilmiş montelukast formülasyonları.
EA201171373A1 (ru) Способы и составы для борьбы с эктопаразитами
JO3192B1 (ar) مركب بنزوثيازولون
EA201401200A1 (ru) Новая композиция альфентанила для лечения острой боли
EA201792122A1 (ru) Кристаллическое соединение как ингибитор фермента семикарбазидчувствительной аминоксидазы (ssao)
TR201005241A1 (tr) Kontrollü salım sağlayan pregabalin solüsyon formülasyonu.
UA110933C2 (uk) Композиція для лікування есенціальної тромбоцитемії
TR201009399A2 (tr) Hızlı çözünen efervesan rosuvastatin formülasyonları.
MX2016014261A (es) Uso de acido 1,3-propandisulfonico o sales farmaceuticamente aceptables del mismo para el tratamiento de sarcoidosis.
EA201491477A1 (ru) Фармацевтические составы, содержащие флупиртин
CL2010001172A1 (es) Composicion farmaceutica solida termoestable que comprende un ingrediente farmaceutico activo de permeabilidad deficiente y al menos una sustancia mejoradora de la permeabilidad, incorporada en forma termoestable en una matriz soluble en agua de un portador soluble en agua; y un proceso para prepararla.